Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia  by Kuo, S.-C. et al.
Evaluation of the effect of appropriate antimicrobial therapy on
mortality associated with Acinetobacter nosocomialis bacteraemia
S.-C. Kuo1,2,3, Y.-T. Lee1,2,4, S.-P. Yang2,5, M.-C. Chiang2,6, Y.-T. Lin1,2, F.-C. Tseng3, T.-L. Chen1,2 and C.-P. Fung1,2
1) Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, 2) Division of Infectious Diseases, Taipei Veterans General
Hospital, Taipei, 3) National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, 4) Department of Medicine,
Chutung Veterans Hospital, Hsinchu County, 5) School of Medicine, National Yang-Ming University, Taipei and 6) Institute of Public Health, School of
Medicine, National Yang-Ming University, Taipei, Taiwan
Abstract
Appropriate antimicrobial therapy is effective for severe infections caused by Acinetobacter baumannii, but efficacy for other Acinetobacter
species remains to be established. The current study was designed to determine whether appropriate antimicrobial therapy reduces the
mortality of patients with Acinetobacter nosocomialis bacteraemia. A 9-year retrospective study of 266 patients with monomicrobial
A. nosocomialis bacteraemia was conducted at a large teaching hospital in Taiwan. Multivariable analysis was performed to evaluate the
impact on 14-day mortality according to clinical characteristics, severity of disease and use of appropriate antimicrobial therapy. The
influence of APACHE II score on the impact of appropriate antimicrobial therapy was analysed by including an interaction term. The
overall 14-day mortality was 9.4%. Multivariable analysis revealed that APACHE II score was the only factor significantly associated with
mortality (odds ratio, 1.18; 95% confidence interval, 1.11–1.25; p <0.001). Appropriate antimicrobial therapy was not associated with
reduced mortality regardless of disease severity. In the subgroup analyses in patients with different clinical conditions, APACHE II score
was consistently an independent factor for 14-day mortality, and appropriate antimicrobial therapy did not affect the mortality in any
group. In conclusion, severity of disease, based on the APACHE II score, was the independent risk factor for 14-day mortality for
patients with monomicrobial A. nosocomialis bacteraemia, even in different clinical conditions. In contrast, appropriate antimicrobial ther-
apy did not reduce the 14-day mortality. The result highlighted a different effect of appropriate antimicrobial therapy on infections
caused by two phenotypically undifferentiated Acinetobacter.
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Introduction
The Acinetobacter baumannii complex (ABC) has become a
leading cause of nosocomial infections [1,2]. ABC is com-
posed of at least three phenotypically undifferentiated Acinet-
obacter species [3]. These include A. baumannii, Acinetobacter
nosocomialis (formally Acinetobacter genomic species 13TU)
and Acinetobacter pittii (formally Acinetobacter genomic species
3) [4,5]. These Acinetobacter species can only be differenti-
ated by molecular methods [5,6]. They differ in antimicrobial
susceptibility, resistance mechanisms and pathogenicity [7–
10]. Among them, A. baumannii and A. nosocomialis account
for most nosocomial infections [10].
Appropriate antimicrobial therapy has been shown to be
highly effective for many infectious diseases [11,12]. How-
ever, the efficacy of appropriate antimicrobial therapy for
treatment of Acinetobacter infections remains controversial
[13–15]. This appears to be confounded by the wide variety
of risk factors, co-morbid illnesses, severity of disease,
differences in pathogenicity of the three Acinetobacter species
and clinical endpoints.
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Several prior studies have revealed major differences in
the clinical characteristics of infections caused by the various
Acinetobacter species [7–10]. Unfortunately, the efficacy of
appropriate antimicrobial therapy for individual species could
not be established because the three Acinetobacter species
were combined in multivariable analyses [7–9]. We recently
found that appropriate antimicrobial therapy reduced the 14-
day mortality for patients with A. baumannii bacteraemia
[16]. This was most pronounced for patients with severe dis-
ease. The current study, consisting of 266 bacteraemic
patients with monomicrobial A. nosocomialis bacteraemia, was
designed to determine whether appropriate antimicrobial
therapy also reduces the mortality of patients with A. noso-
comialis bacteraemia after stratification by demographic char-
acteristics, predisposing factors, severity of disease and
invasive procedures.
Materials and Methods
Study design and data collection
This was a retrospective study conducted at Taipei Veterans
General Hospital (T-VGH) during a 9-year period from 2000
to 2008. T-VGH is a 2900-bed tertiary-care teaching hospital
located in Taipei, Taiwan. Charts were reviewed for all
patients with monomicrobial A. nosocomialis bacteraemia.
Patients were excluded if they were under 18 years old or if
their medical records were not complete.
Medical records were reviewed to extract data, recorded
on a standard form, on demographic characteristics, severity
of disease, predisposing factors, concurrent invasive proce-
dures, infectious foci and concurrent use of intravenous an-
timicrobials. Chronic renal diseases were defined as
estimated glomerular filtration rate (GFR) less than 60 mL/
min/1.73 m2. End-stage renal disease was defined as a GFR
less than 10 mL/min/1.73 m2. Immunosuppressant therapy
was defined as treatment for neoplastic diseases and organ
transplantation, or use of corticosteroids (equivalent to
more than 10 mg of prednisolone daily for 5 days) within
4 weeks of the onset of bacteraemia. Severity of disease
was assessed according to the Acute Physiology and
Chronic Health Evaluation (APACHE) II score within 24 h
of the onset of bacteraemia. This was defined on the day
the positive blood culture for A. nosocomialis was drawn.
The origin of the bacteraemia was defined as previously sug-
gested [17]. Appropriate antimicrobial therapy was defined
as the intravenous administration of at least one antimicro-
bial agent, to which the bacterium was susceptible, at an
appropriate dose within 48 h of onset of bacteraemia [18].
The primary outcome measurement was all-cause 14-day
mortality. This study was approved by the institutional
review board of T-VGH.
Bacterial isolates and identification
Bacterial isolates initially identified as Acinetobacter species by
the API ID 32 GN system (bioMe´rieux, Marcy l’Etoile,
France) or Vitek 2 system (bioMe¢rieux) were collected and
stored at )70C in trypticase soy broth (Difco Laboratories,
Detroit, MI) supplemented with 15% glycerol for the follow-
ing testing. A. baumannii was excluded for analysis after iden-
tification by a multiplex PCR method described previously
[6]. The non-baumannii Acinetobacter was identified to the
species level by sequencing the intergenic space [19]. Only
those confirmed to be A. nosocomialis were selected for fur-
ther testing. The susceptibility of isolates was determined by
the agar dilution test according to the guidelines of the Clini-
cal and Laboratory Standards Institute (CLSI) [18] and the
result was used for determination of the appropriateness of
antimicrobial therapy. Imipenem resistance was defined as a
minimal inhibitory concentration (MIC) of >4 mg/L. Multidrug
resistance was defined as non-susceptible to all agents in at
least three classes of antimicrobial agents. These included
aminoglycosides, ampicillin/sulbactam, fluoroquinolones, anti-
pseudomonas cephalosporins, anti-pseudomonas penicillins
and carbapenems. Colistin and tigecycline were not available
during the study period.
Statistical analysis
Median values and interquartile ranges (IQRs) were used for
continuous variables and the association between non-survi-
vors and survivors was calculated using Student’s t-test or
the Mann–Whitney U-test. Categorical variables were pre-
sented by percentage and calculated with Fisher’s exact test/
Pearson chi-square test, as appropriate. Logistic regression
models were used to explore independent risk factors for
14 and 28-day mortality. All variables with statistical signifi-
cance in univariable analyses were entered into multivariable
analyses to assess their relationship with mortality. Interac-
tions between APACHE II score and the covariates were
also analysed by inclusion of an interaction term. Appropri-
ate antimicrobial therapy and drug resistance were obligato-
rily added into multivariable analysis regardless of univarible
results because they were of interest in the study. Time to
28-day mortality was analysed using Kaplan–Meier survival
analysis (log-rank test). All analyses were performed using
the Statistical Package for the Social Sciences version 18.0
(SPSS, Chicago, IL, USA). A p <0.05 was considered to be
statistically significant.
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Results
Complete clinical data were obtained for 331 patients with
A. nosocomialis bacteraemia during the study period. Sixty-five
(19.6%) with polymicrobial bacteraemia were excluded. The
remaining 266 patients were included in the final analysis.
The 14-day mortality among the patients with monomi-
crobial A. nosocomialis bacteraemia was 9.4%. There were no
significant differences in mortality during the study years
(p 0.498). The clinical characteristics of the patients, resis-
tance profiles, use of antimicrobial agents and appropriate-
ness of therapy are shown in Table 1 according to 14-day
mortality. Patients who died within 14 days following the
onset of bacteraemia were significantly more likely to be
older, have higher APACHE II scores, nasogastric tubes,
mechanical ventilation, central venous catheters, the respira-
tory tract as the infectious foci and concurrent use of fluor-
oquinolones compared with those who survived. There were
no significant differences in the rates of patients who
received appropriate antimicrobial therapy between non-sur-
vivors and survivors (48.0% vs. 51.0%, p 0.937). There were
no significant differences regarding the proportions of imipe-
nem-resistant isolates (24.0% vs. 17.8%, p 0.424) or multi-
drug-resistant isolates (12.0% vs. 6.2%, p 0.232) between the
two groups. In addition to all statistically significant variables,
appropriateness of antimicrobial therapy and imipenem- and
multidrug-resistant rate of the isolates were also entered
into a multivariable analysis (Table 2). The APACHE II score
was found to be the only independent risk factor for 14-day
mortality (odds ratio, 1.18; 95% confidence interval, 1.11–
1.25; p <0.001) and 28-day mortality (Table S1). Appropri-
ateness of antimicrobial therapy did not affect the outcome.
Kaplan–Meier survival analysis also revealed that appro-
priate antimicrobial therapy (p 0.157; Fig. 1), imipenem
resistance (p 0.564) and multidrug resistance (p 0.388; Fig-
ure not shown) did not affect the time to death during 28-
day follow up.
It has been suggested that the impact of appropriate
antimicrobial therapy is affected by the patient disease
severity [20,21]. Therefore, the interaction term of
APACHE II scores and appropriateness of antimicrobial
therapy or drug resistance were included in multivariable
analyses. However, no statistical significance was found. An
APACHE II score >25 has been associated with worse out-
come in patients with sepsis [22]. The patients were strati-
fied into two groups based on APACHE II score £25 or
>25. However, appropriateness of antimicrobial therapy did
not reduce 14-day mortality in either group (p 0.467 and
0.552, respectively).
To identify the impact of appropriate antimicrobial therapy
in other subgroups, we further stratified patients according
to different clinical characteristics, as shown in Table 3.
TABLE 1. Clinical characteristics of patients with Acineto-
bacter nosocomialis bacteraemia who survived or died within
14 days after the onset of bacteraemia
Characteristics
Non-survivors
(n = 25)
Survivors
(n = 241) p value
Demographic data
Age, years 78 (71.5–82) 72 (57–80) 0.054
Male sex 18 (72.0) 171 (71.0) >0.99
Hospitalization duration prior to
bacteraemia, days
15 (13–23) 15 (8–26) 0.246
Bacteraemia onset in ICU 16 (64.0) 120 (49.8) 0.253
APACHE II score within 24 h of
bacteraemia onset
31 (25–38) 18 (14–24.5) <0.001
Predisposing factors
Use of immunosuppressant 11 (44.0) 74 (30.7) 0.258
Solid organ tumour 9 (36.0) 90 (37.3) >0.99
Cerebrovascular diseases 7 (28.0) 44 (18.3) 0.283
Smoking 7 (28.0) 39 (16.2) 0.162
Diabetes mellitus 6 (24.0) 62 (25.7) >0.99
Hypertension 5 (20.0) 79 (32.8) 0.279
Chronic lung diseases 5 (20.0) 39 (16.2) 0.579
Chronic renal disease 4 (16.0) 43 (17.8) >0.99
Alcoholism 4 (16.0) 21 (8.7) 0.271
Major operation 3 (12.0) 63 (26.1) 0.189
Coronary artery disease 1 (4.0) 43 (17.8) 0.091
Congestive heart failure 1 (4.0) 26 (10.8) 0.487
ESRD 1 (4.0) 15 (6.2) >0.99
PAOD 1 (4.0) 5 (2.1) 0.450
Liver cirrhosis 0 (0) 17 (7.1) 0.383
Haematological malignancy 0 (0) 14 (5.8) 0.375
Trauma 0 (0) 13 (5.4) 0.619
Autoimmune diseases 0 (0) 10 (4.1) 0.606
Neutropenia 0 (0) 8 (3.3) >0.99
Concurrent invasive procedures
Nasogastric tube 19 (76.0) 113 (46.9) 0.010
Mechanical ventilation 18 (72.0) 90 (37.3) 0.002
Central venous catheterization 17 (68.0) 106 (44.0) 0.037
Foley catheter 16 (64.0) 120 (49.8) 0.253
Arterial catheterization 6 (24.0) 42 (17.4) 0.416
Pulmonary arterial line 4 (16.0) 23 (9.5) 0.298
Abdominal drainage 2 (8.0) 16 (6.6) 0.681
FVC 2 (8.0) 10 (4.1) 0.313
Tracheostomy 1 (4.0) 25 (10.4) 0.486
Thoracic drain 1 (4.0) 14 (5.8) >0.99
Total parental nutrition 1 (4.0) 12 (5.0) >0.99
Arterio-venous fistula 1 (4.0) 3 (1.2) 0.328
Infectious foci
Respiratory tract 17 (68.0) 107 (44.4) 0.041
Primary bacteraemia 6 (24.0) 65 (27.0) 0.935
Catheter-related 1 (4.0) 27 (11.2) 0.490
Intra-abdomen 1 (4.0) 15 (6.2) >0.99
Soft tissue or wound 0 (0) 15 (6.2) 0.374
Urinary tract 0 (0) 12 (5.0) 0.611
Resistance profile
Imipenem-resistant isolates 6 (24.0) 43 (17.8) 0.424
Multidrug-resistant isolates 3 (12.0) 15 (6.2) 0.232
Concomitant intravenous antibiotic use
Anti-pseudomonal
cephalosporins
6 (24.0) 47 (19.5) 0.601
Aminoglycosides 5 (20.0) 56 (23.2) 0.907
Sulbactam or ampicillin/sulbactam 3 (12.0) 27 (11.2) >0.99
Fluoroquinolones 3 (12.0) 7 (2.9) 0.057
Anti-pseudomonal penicillins 2 (8.0) 25 (10.4) >0.99
Carbapenems 1 (4.0) 18 (7.5) >0.99
Aztreonam 1 (4.0) 2 (0.8) 0.257
TMP/SXT 1 (4.0) 2 (0.8) 0.257
Appropriate antimicrobial
therapy
12 (48.0) 123 (51.0) 0.937
Data are median value (interquartile range) for continuous variables and number
of cases (%) for categorical variables.
ICU, intensive care unit; APACHE II, Acute Physiology and Chronic Health Eval-
uation II; ESRD, end-stage renal disease; PAOD, peripheral arterial occlusive dis-
ease; FVC, femoral venous catheterization; TMP/SXT, trimethoprim-
sulphamethoxazole.
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Multivariable analysis revealed that higher APACHE II score
was consistently the independent factor for poor prognosis
whereas the use of appropriate antimicrobial therapy or drug
resistance was not correlated with the mortality.
Discussion
This retrospective analysis of 266 patients with monomi-
crobial A. nosocomialis bacteraemia admitted to a large
teaching hospital in Taiwan revealed that appropriate anti-
microbial therapy was not associated with a reduction in
14-day mortality even after adjustment for APACHE II
scores, clinical characteristics and microbiological findings.
The only independent factor for 14-day mortality was the
severity of disease.
Most studies that have attempted to delineate the rela-
tionship between antimicrobial therapy and mortality
included all ABCs without further identification [13–15]. Sev-
eral pilot studies in which ABCs were identified to the spe-
cies level also failed to distinguish outcomes in relation to
whether the infection was caused by A. baumannii or A. noso-
comialis [7–9]. We recently reported that use of appropriate
antimicrobial therapy significantly reduced 14-day mortality
in patients with A. baumannii [16]; however, the current
study demonstrated that severity of disease, but not appro-
priateness of antimicrobial therapy, was the major risk factor
for 14-day mortality. These findings at least partly explained
the inconsistent effect of antimicrobial therapy in previous
studies, which might consist of different proportions of ABC
species [13–15].
It is sometimes difficult to demonstrate the effect of anti-
microbial therapy on the mortality of patients infected with
pathogens of low virulence [23–25]. Similar to A. nosocomialis,
the Enterococcus species is also a pathogen of low virulence
[25]. Several studies have also failed to show an advantage of
appropriate antimicrobial therapy for infections associated
with Enterococcus species, particularly in non-compromised
hosts. Nevertheless, many studies have revealed the impact
of prompt use of adequate antimicrobial agents on seriously
ill or immunocompromised hosts [23–25]. The effect of anti-
microbial therapy was also varied among subgroups of
patients with different disease severity, underlying diseases
or infection foci [11,20,23,25,26]. However, we did not find
TABLE 2. Factors associated with 14-day mortality in
patients with Acinetobacter nosocomialis bacteraemia
Characteristics
Univariable analysis
Multivariable
analysis
OR (95% CI) p value
OR
(95% CI) p value
Age 1.03 (1.00–1.07) 0.054
APACHE II score 1.18 (1.11–1.25) <0.001 1.18
(1.11–1.25)
<0.001
Nasogastric tube 3.59 (1.38–9.29) 0.009
Mechanical ventilation 4.31 (1.73–10.73) 0.002
Central venous
catheterization
2.71 (1.13–6.51) 0.026
Respiratory infections 2.66 (1.11–6.04) 0.029
Fluoroquinolones therapy 4.56 (1.10–18.89) 0.036
Multidrug-resistant isolates 2.06 (0.55–7.65) 0.283
Imipenem-resistant isolates 1.45 (0.55–3.86) 0.452
Appropriate antimicrobial
therapy
0.89 (0.39–2.02) 0.773
OR, odds ratio; CI, confidence interval; APACHE II, Acute Physiology and
Chronic Health Evaluation II.
FIG. 1. Kaplan–Meier survival curves at 28 days after Acinetobacter
nosocomialis bacteraemia onset for patients with appropriate and
inappropriate antimicrobial therapy.
TABLE 3. Multivariable analyses of predictors of 14-day
mortality among different subgroups of patients with Aci-
netobacter nosocomialis bacteraemia
Subgroup
characteristics
Independent
factor(s)a OR (95% CI) p value
Predisposing factors and invasive procedures
Immunocompromised
hostsb (n = 150)
APACHE II score 1.18 (1.08–1.30) <0.001
Solid organ or
haematological
malignancy (n = 111)
APACHE II score 1.17 (1.06–1.29) 0.010
Use of mechanical
ventilation (n = 108)
APACHE II score 1.15 (1.06–1.24) <0.001
Use of
immunosuppressants
(n = 85)
APACHE II score 1.11 (1.03–1.20) 0.005
Diabetes mellitus
(n = 68)
APACHE II score 1.29 (1.07–1.57) 0.007
Infection foci
Respiratory tract
(n = 124)
APACHE II score 1.17 (1.08–1.27) <0.001
Major operation 0.10 (0.01–0.98) 0.048
Primary bacteraemia (n = 71) APACHE II score 1.27 (1.08–1.50) 0.005
OR, odds ratio; CI, confidence interval; APACHE II, Acute Physiology and
Chronic Health Evaluation II.
aAppropriate antimicrobial therapy, drug-resistance and variables with p <0.1
under univariable analyses were all entered into multivariable analysis in each
subgroup.
bDefined as those who had autoimmune diseases, neutropenia or any types of
cancer, or received radiation therapy or any immunosuppressive agents.
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that the appropriate antimicrobial therapy would increase
survival rate in any subgroups of patients with A. nocosomialis
bacteraemia, either in immunocompromised hosts or those
with higher disease severity. On the contrary, the severity of
disease as indicated by higher APACHE II score was consis-
tently the risk factor for mortality in all subgroup popula-
tions, indicating that the underlying conditions and disease
severity of the patients played a much more important role
than appropriate therapy in patients with A. nosocomialis bac-
teraemia. In the patients with higher APACHE II score, the
dysregulated immune system might fail to conquer the low
pathogenic A. nosocomialis and contribute to the poor out-
come. It has also been demonstrated that in combat casual-
ties, the higher APACHE II scores are associated with
persistent higher levels of proinflammatory cytokines [27].
This immune dysfunction is associated with the acquisition of
Acinetobacter wound infection [28] and impaired wound heal-
ing [27].
The strength of this study is the inclusion of the largest
group of patients with well-defined monomicrobial A. noso-
comialis bacteraemia seen at a large teaching hospital over a
9-year period. The weakness is the ethical necessity to con-
duct a retrospective analysis to compare appropriate versus
inappropriate therapy. Another limitation is the low number
of patients with mortality, which might limit the detection of
the difference in appropriateness of antimicrobial therapy
between the two groups of patients. It would be unwise to
conclude that appropriate antimicrobial therapy is not useful
for treatment of infections caused by A. nosocomialis. Further
studies are needed to evaluate the effect of antimicrobial
therapy on the outcome of infections at specific body sites
and on duration of hospital stay and to identify the patients
who would mostly benefit from appropriate therapy.
In conclusion, severity of disease, based on the APACHE
II score, was the only independent risk factor for 14-day
mortality for patients with monomicrobial A. nosocomialis
bacteraemia. Appropriate or inappropriate use of antibiotics
had less effect on 14-day mortality.
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